# Genomedia

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/genomedia

- Industry: Healthcare IT
- Headquarters: Tokyo, Japan
- Website: https://genomedia.jp
- Total disclosed funding: $9M
- Latest round: Series B (Oct 26, 2020)
- Investors on record: 4

## About

Genomedia Inc. is a Japan-based company specializing in advanced genomic analysis solutions to enhance research and clinical applications in the life sciences sector.Founded in 2013, Genomedia Inc. is headquartered in Tokyo, Japan, and focuses on genomic data analysis. The company has successfully completed 2 funding deals, with its most recent Series B round occurring on October 26, 2020, raising JPY 655 million from investors including Aflac Corporate Ventures, Ship Healthcare Holdings, and Sumitomo Corporation. The founder and CEO, Tomoyuki Yamada, has been instrumental in steering the company through its funding milestones and strategic partnerships, which are pivotal for its growth and operations.Genomedia offers a range of advanced genomic analysis tools and services aimed at enhancing research and clinical applications in the life sciences sector. The company’s core product is a sophisticated genomic data analysis platform that utilizes proprietary algorithms to interpret complex genetic data. This platform serves various end use cases, including personalized medicine, drug development, and disease prevention strategies, addressing the growing demand for tailored healthcare solutions. Genomedia’s customer base comprises research institutions, pharmaceutical companies, and healthcare organizations globally, particularly in North America, Europe, and parts of Asia. By leveraging its technology, Genomedia enables users to gain actionable insights from genetic information, fostering innovations in medical research and treatment outcomes.Genomedia generates revenue through a business model that includes subscription services, partnerships, and direct sales to its clients. The company offers tiered subscription plans that provide access to its genomic analysis platform, with features catering to the varying needs of research institutions and healthcare providers. Additionally, Genomedia collaborates with pharmaceutical companies on a project basis, where revenue is generated from customized data analysis services and consulting. The transactions typically involve multi-year agreements with established pricing structures tailored to the specific capabilities and analytical depth required by clients. The flagship offerings play a significant role in establishing the company’s market presence and ensuring steady revenue streams from its diverse clientele.In October 2020, Genomedia raised JPY 655 million in Series B funding, which will significantly support its future growth initiatives. This funding coincides with a partnership with Sumitomo and Ship Healthcare to enhance the provision of medical-related information services for research institutions and healthcare providers. The company plans to utilize these funds to accelerate the discovery of drugs using genomic treatment information, thereby improving the quality of genome medical treatment. Additionally, Genomedia aims to expand its market presence in North America and Europe by launching new products tailored for specific medical applications by mid-2023.

## Funding rounds

- Series B, Oct 26, 2020, $6.3M — Sumitomo Corporation, Aflac Corporate Ventures, Ship Healthcare Holdings
- Series A, Aug 1, 2017, $2.7M — JAFCO Group

## Investors

- JAFCO Group (https://capitalatlas.ai/funds/jafco-group) — Series A
- Sumitomo Corporation — Series B
- Aflac Corporate Ventures (https://capitalatlas.ai/funds/aflac-corporate-ventures) — Series B
- Ship Healthcare Holdings — Series B